| 0.9903 -0.03 (-2.91%) | 10-04 11:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.26 | 1-year : | 1.47 |
| Resists | First : | 1.08 | Second : | 1.26 |
| Pivot price | 0.93  |
|||
| Supports | First : | 0.83 | Second : | 0.68 |
| MAs | MA(5) : | 1 |
MA(20) : | 0.87 |
| MA(100) : | 0.83 |
MA(250) : | 0.9 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 80.3 | D(3) : | 80.3 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 1.75 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACHL ] has closed below upper band by 35.8%. Bollinger Bands are 225.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.02 - 1.03 | 1.03 - 1.03 |
| Low: | 0.96 - 0.97 | 0.97 - 0.97 |
| Close: | 1.01 - 1.02 | 1.02 - 1.03 |
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Mon, 23 Sep 2024
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Thu, 19 Sep 2024
Achilles Therapeutics ends TIL-based cancer therapy trials - Investing.com
Thu, 19 Sep 2024
Achilles stock climbs on strategic focus (NASDAQ:ACHL) - Seeking Alpha
Thu, 19 Sep 2024
Achilles Therapeutics Shares Are Trading Higher: What You Need To Know - Benzinga
Thu, 19 Sep 2024
Achilles Therapeutics Announces Strategic Update - StockTitan
Thu, 19 Sep 2024
Achilles Therapeutics Announces Strategic Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 41 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 62.4 (%) |
| Shares Short | 4 (K) |
| Shares Short P.Month | 8 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.9 % |
| Return on Equity (ttm) | -44.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | -0.1 |
| Price to Book value | 0.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|